Cell surface expression of human RP105 depends on N-glycosylation of MD-1.
FEBS Lett
; 596(24): 3211-3231, 2022 12.
Article
en En
| MEDLINE
| ID: mdl-35849076
ABSTRACT
For its cell surface expression, radioprotective 105 (RP105) - an orphan Toll-like receptor - must form a complex with a soluble glycoprotein called myeloid differentiation 1 (MD-1). The number of RP105-negative cells is significantly increased in patients with systemic lupus erythematosus (SLE); however, to elucidate the mechanism underlying this increase, how RP105 is expressed on the cell surface depending on MD-1 should be investigated. We demonstrated that RP105 exhibits two forms depending on MD-1 and its two N-glycosylation sites, N96 and N156. Cell surface expression of RP105 decreased in the presence of mutant MD-1 (N96Q/N156Q). Nonglycosylated MD-1 decreased the de novo cell surface expression of RP105 but not pre-expressed RP105. Thus, the N-glycans of MD-1 may represent targets for SLE therapy.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Lupus Eritematoso Sistémico
/
Antígenos de Superficie
Límite:
Humans
Idioma:
En
Revista:
FEBS Lett
Año:
2022
Tipo del documento:
Article
País de afiliación:
Japón